Clinical trials: Antipsychotic
Neutropenia
Hematological Effects of Atypical Antipsychotics (AAPs) in a Geriatric Population: What is the Role of 5-HT2 Receptors
White lineage abnormalities and in particular neutropenia and agranulocytosis are known and increasingly studied adverse effects of antipsychotics, particularly second generation.
- Trial name
- AAPs (NCT06107322)
- Where
- France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Strasbourg, France
Schizophrenia, Schizoaffective Disorder
A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents
Lurasidone (lurasidone HCl) is a novel psychotropic agent that is being developed as a potential new antipsychotic treatment for patients with schizophrenia.
- Trial name
- SWITCHCore (NCT01143077)
- Testing
- Lurasidone HCl
- Where
- 27 sites in United States
- Volunteers
- 244 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia
Different Safety Profile of Risperidone and Paliperidone Extended-release
The main objective of this study was to assess subjective experiences related to secondary negative symptoms and cognitive performance in healthy volunteers in response to multiple doses of paliperidone ER and risperidone in a…
- Trial name
- NCT01284959
- Testing
- risperidone, paliperidone ER
- Where
- South Korea
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Chonbuk National University Hospital
Schizophrenia, Schizoaffective Disorder
A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis
The purpose of this study is to evaluate the effectiveness, safety and tolerability of risperidone long-acting injection (LAI) versus oral antipsychotics in participants with recent onset psychosis (abnormal thinking and/or…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorders
- Trial name
- NCT00246259
- Testing
- Risperidone long-acting injection (LAI), Oral Antipsychotic
- Where
- 11 sites in Canada
- Volunteers
- 77 people
- Sponsor
- Janssen-Ortho Inc., Canada
Schizophrenia, Antipsychotic Induced Weight Gain
A Relation Between Craving Induction and Treatment Response in Deep Transcranial Magnetic Stimulation (dTMS) for Reducing Antipsychotic-induced Weight Gain in Schizophrenia
Antipsychotic-induced metabolic disturbances, especially weight gain, are common in patients with schizophrenia. Furthermore, it is reported significant changes in food intake happened in patients with weight gain after intaking…
- Trial name
- dTMS (NCT07805980)
- Testing
- Deep Transcranial Magnetic Stimulation (dTMS) H4 coil - Active
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Xiangya Hospital of Central South University
Schizophrenia
Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
This is a Phase 3, randomized, double blind, placebo controlled, fixed dose, study designed to evaluate the efficacy, safety, tolerability, and of LB-102 versus placebo for the treatment of adult patients with an acute…
- Trial name
- NOVA2 (NCT07363577)
- Testing
- LB-102 (50 mg tablet), LB-102 (100 mg tablet)
- Where
- 13 sites in United States
- Volunteers
- 456 people
- Sponsor
- LB Pharmaceuticals Inc.
Schizophrenia
Safety and Efficacy of an Anti-Psychotic in Patients With Schizophrenia
The purpose of this study is to determine the efficacy (how well the drug works), safety, and side effects of paliperidone palmitate injection compared to placebo in the treatment of the symptoms of schizophrenia in adults.
- Trial name
- NCT00074477
- Testing
- R092670
- Volunteers
- 250 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Phase 4 Study to Evaluate Efficacy of Paliperidone Extended-Release(ER) in Schizophrenic Participants
The purpose of this study is to investigate the efficacy of flexibly dosed paliperidone extended-release (mechanism to dissolve a drug over time in order to be released slower and steadier into the blood stream) in improving or…
- Trial name
- PASS (NCT00761605)
- Testing
- Paliperidone
- Where
- 8 sites in South Korea
- Volunteers
- 387 people
- Sponsor
- Janssen Korea, Ltd., Korea
Antipsychotic Induced Weight Gain
: EFFECT OF PROBIOTIC SUPPLEMENTATION ON ATYPICAL ANTIPSYCHOTIC INDUCED WEIGHT GAIN IN PATIENTS ATTENDING PSYCHIATRIC CLINICS AT AINSHAMS UNIVERSITY HOSPITALS (A RANDOMIZED CONTROLLED TRIAL)
the goal of the study is to improve the quality of life of patients on antipsychotic medications and increase the rate of compliance to treatment.
- Trial name
- NCT06936137
- Testing
- lactobacillus LS
- Where
- Egypt
- Volunteers
- 180 people
- Sponsor
- Ain Shams University
Mental Illness
Behavioral Intervention to Reduce Novel Antipsychotic Medication Health Risks
This study will evaluate the effectiveness of a cognitive behavioral treatment in reducing significant medical risk factors often associated with people who have a serious mental illness and are taking atypical antipsychotic…
- Trial name
- NCT00709345
- Testing
- Cognitive behavioral sessions, Time-matched attention control sessions
- Volunteers
- 333 people
- Sponsor
- Medical College of Wisconsin
Schizophrenia
Efficacy of Bifeprunox in Patients With Schizophrenia
The primary purpose of the study is to evaluate the efficacy of bifeprunox in the maintenance phase of schizophrenia compared to placebo.
- Trial name
- NCT00704509
- Testing
- Bifeprunox, Quetiapine
- Where
- 45 sites in India, Indonesia and 5 more
- Volunteers
- 346 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia, Alzheimer's Disease
Side Effects of Newer Antipsychotics in Older Adults
This study will compare four atypical antipsychotic medications in terms of the risk of specific side effects each of them presents in middle-aged and elderly individuals.
- Conditions
- Schizophrenia, Alzheimer's Disease, Dementia
- Trial name
- NCT00245206
- Testing
- Aripiprazole, Olanzapine, Risperidone
- Where
- United States
- Volunteers
- 406 people, healthy volunteers welcome
- Sponsor
- Veterans Medical Research Foundation
Schizophrenia
Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study
Despite recent advances in the understanding and treatment of schizophrenia, this devastating disease still affects one percent of world's population.
- Trial name
- CBD-IS (NCT02051387)
- Testing
- Cannabidiol CR, Cannabidiol, Amisulpride
- Where
- 2 sites in Germany
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Central Institute of Mental Health, Mannheim
Schizophrenia, Schizoaffective Disorder
Tetrabenazine for Partial Responders
Purpose of Study: A) To improve outcome in large population of antipsychotic patients with schizophrenia or schizoaffective who are only partial responders B) To increase understanding of pharmacology and mechanisms of action…
- Trial name
- NCT00362804
- Testing
- Tetrabenazine
- Where
- Canada
- Volunteers
- 41 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia
Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole
The purpose of this study is to compare retrospective hospitalization rates of schizophrenic patients treated with oral antipsychotics to prospective hospitalization rates of these patients treated with IM depot aripiprazole.
- Trial name
- ARRIVE US (NCT01432444)
- Testing
- Aripiprazole (Abilify®) IM Depot Injection
- Where
- 124 sites in United States, Canada
- Volunteers
- 493 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Antipsychotic Discontinuation in High-risk Subjects
Would be there any difference in dopamine synthesis between remitted clinical high risk subjects for psychosis and healthy control? What would happen to dopamine synthesis after antipsychotic discontinuation in clinical high risk…
- Trial name
- NCT01758887
- Where
- South Korea
- Volunteers
- healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Tardive Dyskinesia, Antipsychotic Agents
Randomized Controlled Trial of Pyridoxine for Tardive Dyskinesia
Purpose: Tardive dyskinesia (TD) is a involuntary movement disorder that can occur following long term treatment with antipsychotic medications and for which few treatment options exist.
- Trial name
- NCT03287778
- Testing
- Pyridoxine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of North Carolina, Chapel Hill
Metabolic Syndrome, Schizophrenia
Topiramate vs Metformin on Cardio-Metabolic Profile in Schizophrenia on Atypical Antipsychotics
Metabolic syndrome is common in patients of schizophrenia. It can add to morbidity, loss of functionality and discontinuation of antipsychotic medication.
- Trial name
- NCT05663749
- Testing
- Metformin, Topiramate
- Where
- India
- Volunteers
- 60 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Schizophrenia
Comparison of a Long-acting Injectable Antipsychotic vs Clinician's Choice Early in Treatment to Break the Cycle of Relapse in Early Phase Schizophrenics
The goal of this project is to show that the best possible option for preventing relapses in patients suffering from first episode (<1 year of anti-psychotic medication) or early phase (< 5 years of lifetime exposure to…
- Trial name
- PRELAPSE (NCT02360319)
- Testing
- Any FDA approved antipsychotic agent, aripiprazole long acting injectable formulation
- Where
- 39 sites in United States
- Volunteers
- 489 people
- Sponsor
- Vanguard Research Group
Schizophrenia
One Year Drug Treatment in First-Episode Schizophrenia
Prospective, randomized, double-blind, multi-center study on 1 year course and treatment outcome under low-dose typical (haloperidol) vs. atypical neuroleptics (risperidone) in first-episode schizophrenia.
- Trial name
- NCT00159081
- Testing
- Haloperidol, Risperidone (drug)
- Where
- Germany
- Volunteers
- 159 people
- Sponsor
- Heinrich-Heine University, Duesseldorf